How Endometriosis Develops and Spreads Beyond the Uterus

Tissue in Places It Was Never Meant to Grow

Endometriosis affects an estimated 190 million women and girls of reproductive age worldwide, roughly 10 percent of that population, according to the World Health Organization. The condition occurs when tissue similar to the endometrium, the lining of the uterus, grows outside the uterine cavity. These implants most commonly appear on the ovaries, fallopian tubes, pelvic peritoneum, and the cul-de-sac (the space between the uterus and rectum). In rare cases, endometrial-like tissue has been found in the diaphragm, lungs, and even the brain.

The average diagnostic delay is 7 to 10 years from symptom onset. This gap exists because symptoms overlap with other conditions, pain is frequently normalized, and definitive diagnosis historically requires surgery. That delay means millions of women live with undiagnosed chronic pain during their most productive years.

Theories of Origin: How It Gets There

No single theory fully explains endometriosis. Several mechanisms likely contribute in different patients.

Genetics plays a substantial role. First-degree relatives of affected women have a 5 to 7 times higher risk. Genome-wide association studies have identified multiple susceptibility loci, many related to hormone signaling and immune function.

The Inflammatory Cycle That Feeds on Itself

Endometriotic implants respond to estrogen just like the uterine lining. They thicken, break down, and bleed with each menstrual cycle. But unlike normal endometrial tissue shed through the cervix, this blood has no exit. The trapped blood and cellular debris trigger a chronic inflammatory response.

Macrophages, mast cells, and T cells infiltrate the lesions. Pro-inflammatory cytokines (IL-1, IL-6, IL-8, TNF-alpha) flood the surrounding tissue. This inflammatory milieu promotes angiogenesis (new blood vessel formation), which feeds the implants and allows them to grow. The implants themselves produce their own estrogen through local aromatase expression, creating a self-sustaining loop independent of ovarian hormones.

Over time, the chronic inflammation leads to adhesion formation. Organs that should glide freely against each other become stuck together. Dense scar tissue can distort pelvic anatomy, obliterate the cul-de-sac, and encase the ovaries.

Symptoms: Far More Than Period Pain

Endometriosis produces a range of symptoms, and severity does not always correlate with disease extent. Some women with minimal disease have debilitating pain, while others with extensive involvement are asymptomatic.

• Dysmenorrhea: painful periods that progressively worsen over time
• Chronic pelvic pain: present outside of menstruation in 40-60% of patients
• Dyspareunia: deep pain during or after intercourse
• Dyschezia: painful bowel movements, especially during menstruation
• Dysuria: painful urination when bladder endometriosis is present
• Infertility: affects 30-50% of women with endometriosis
• Fatigue: chronic and disproportionate to activity level
• Bloating and gastrointestinal symptoms that mimic irritable bowel syndrome

Staging and Classification

The revised American Society for Reproductive Medicine (rASRM) staging system assigns points based on implant location, depth, and extent of adhesions. Stages range from I (minimal) to IV (severe). This system has limitations: it does not correlate well with pain severity or predict fertility outcomes.

Endometriomas, also called chocolate cysts, are ovarian cysts filled with old blood. They form when endometriosis invades the ovary. Endometriomas larger than 4 cm often require surgical excision, particularly when fertility preservation is a priority.

Treatment: Pain Management and Fertility Preservation

Treatment strategy depends on the primary complaint: pain, infertility, or both. Medical therapy for pain focuses on suppressing estrogen to starve the implants.

• NSAIDs: first-line for mild pain, symptom relief only
• Combined oral contraceptives: suppress ovulation, thin the endometrium
• Progestins (norethindrone, dienogest, medroxyprogesterone): create a pseudo-decidual state
• GnRH agonists (leuprolide) and antagonists (elagolix): induce medical menopause, limit use to 6-12 months due to bone loss
• Aromatase inhibitors: block local estrogen production within implants

Surgical excision via laparoscopy remains the gold standard for definitive diagnosis and treatment of moderate to severe disease. Excision of deep infiltrating endometriosis by experienced surgeons reduces pain in 60 to 80 percent of patients. Recurrence rates, however, reach 40 to 50 percent within 5 years after surgery.

For infertility, treatment depends on disease severity and other factors. Mild endometriosis may respond to ovulation induction with intrauterine insemination. Moderate to severe disease often requires in vitro fertilization (IVF). Surgical removal of endometriomas before IVF is debated because it may reduce ovarian reserve. This article is for informational purposes only. Consult a qualified professional.